arrow
J

José M. Moraleda

university of murcia
H指数:51
被引数:8,822

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Phase IIB, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Intravenous Defibrotide for the Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome in COVID-19

II期B阶段,随机、双盲、安慰剂对照临床试验:静脉注射去纤苷预防及治疗COVID-19患者的呼吸窘迫和细胞因子释放综合征

2026-01-010
OAAI
Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

新诊断的移植不合格的多发性骨髓瘤患者的免疫麻痹恢复,这是补充最小残留疾病的独立预后因素

2024-10-230
PRE
Endothelial injury and dysfunction with emerging immunotherapies in multiple myeloma, the impact of COVID-19, and endothelial protection with a focus on the evolving role of defibrotide

多发性骨髓瘤中新兴免疫疗法的内皮损伤和功能障碍,新型冠状病毒肺炎的影响以及内皮保护作用,重点是去纤维蛋白多核苷酸的演变作用

2024-07-010
OAAI
Optimizing cryopreservation conditions for use of fucosylated human mesenchymal stromal cells in anti-inflammatory/immunomodulatory therapeutics

优化岩藻糖基化人间充质基质细胞在抗炎/免疫调节治疗中的冷冻保存条件

2024-03-280
OAAI
Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

学术BCMA-CART ARI0002h治疗难治性多发性骨髓瘤的疗效和安全性的生物标志物

2024-03-114
PRE
Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection

在新诊断的符合移植条件的骨髓瘤患者中恢复未涉及的重链/轻链对免疫麻痹,补充了微小残留病检测的预后价值

2023-11-304
OAAI
A Newborn Screening Program for Sickle Cell Disease in Murcia (Spain)

穆尔西亚 (西班牙) 镰状细胞病的新生儿筛查计划

2023-10-102
OAAI
Large T cell clones expressing immune checkpoints increase during multiple myeloma evolution and predict treatment resistance
2023-09-206
OAAI
Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications
2022-10-046
OAAI
Optimization of Mesenchymal Stromal Cell (MSC) Manufacturing Processes for a Better Therapeutic Outcome

优化间充质基质细胞 (MSC) 制造工艺以获得更好的治疗效果

2022-06-0956
OAAI
Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma
2022-05-3129
OAAI
Hematopoietic cell transplantation in severe combined immunodeficiency: The SCETIDE 2006-2014 European cohort

严重联合免疫缺陷的造血细胞移植: SCETIDE 2006 2014的欧洲队列

2022-05-0159
OA